降低射出分数的心力衰竭的设备疗法:一个新时代
Rohit Mody1, Abha Bajaj Nee Sheth2, Debabrata Dash3
1Department of Cardiology, Mody Harvard Cardiac Institute & Research Centre, Krishna Super Specialty Hospital, Bathinda, India.
Frontiers in cardiovascular medicine
|November 4, 2024
概括
基于导管的新疗法为治疗慢性心力衰竭 (HF) 提供了希望. 这些创新的治疗方法针对关键的HF过程,以改善患者的生活质量和减少住院治疗.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 干预心脏病学 干预心脏病学
背景情况:
- 尽管有进展,心力衰竭 (HF) 仍然具有很高的发病率和死亡率.
- 目前的高频管理包括诸如心脏再同步治疗和左心室辅助设备等设备.
- 需要改进治疗方法,以减少住院和提高HF患者的生活质量.
研究的目的:
- 审查用于管理慢性心力衰竭 (HF) 的主要透导管器件.
- 讨论这些基于导管的新型疗法背后的逻辑.
- 概述这些干预措施目前的临床开发阶段.
主要方法:
- 对治疗慢性高频率的跨导管器件当前文献的综述.
- 对病理生理学目标的分析,包括神经道激活,拥堵和左心室重塑.
- 检查新兴导管治疗的临床发展状态.
主要成果:
- 几种非膜导管式疗法正在出现,用于慢性HF管理.
- 这些设备旨在解决核心高频机制.
- 审查详细介绍了这些干预措施的当前进展和潜力.
结论:
- 过导管装置在治疗慢性心力衰竭方面是一个有前途的前沿.
- 进一步的研究和开发对于优化这些疗法至关重要.
- 这些创新有可能显著改善HF患者的治疗结果.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
Heart Failure Drugs: Inotropic Agents
525
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2


